<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03400241</url>
  </required_header>
  <id_info>
    <org_study_id>3122002</org_study_id>
    <nct_id>NCT03400241</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study Comparing Tiotropium Easyhaler and Spiriva Handihaler</brief_title>
  <official_title>Pharmacokinetic Pilot Study Comparing Absorption of Inhaled Tiotropium Between Tiotropium Easyhaler® Products and Spiriva® Capsules Delivered Via HandiHaler®</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orion Corporation, Orion Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orion Corporation, Orion Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Absorption of inhaled tiotropium is compared between three Tiotropium Easyhaler products and
      Spiriva capsules inhaled via HandiHaler. All subjects will receive all products as a single
      dose.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 19, 2018</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak plasma concentration (Cmax) of tiotropium</measure>
    <time_frame>between 0-72 hours after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve (AUC) of tiotropium from time zero to 72 h after the study treatment administration</measure>
    <time_frame>0-72 hours after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Truncated area under the concentration-time curve (AUC) of tiotropium from time zero to 30 min after study treatment administration</measure>
    <time_frame>0-30 minutes after dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to reach peak concentration in plasma (tmax) of tiotropium</measure>
    <time_frame>between 0-72 hours after dosing</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>throughout the study, an average of 10 weeks</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Tiotropium Easyhaler Product A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tiotropium bromide monohydrate 2 inhalations as a single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiotropium Easyhaler Product B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tiotropium bromide monohydrate 2 inhalations as a single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiotropium Easyhaler Product C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tiotropium bromide monohydrate 2 inhalations as a single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Spiriva HandiHaler</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tiotropium bromide monohydrate 2 Spiriva capsules inhaled via HandiHaler</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium Bromide Monohydrate</intervention_name>
    <description>Tiotropium Easyhaler 10 mcg/dose Product A</description>
    <arm_group_label>Tiotropium Easyhaler Product A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium Bromide Monohydrate</intervention_name>
    <description>Tiotropium Easyhaler 10 mcg/dose Product B</description>
    <arm_group_label>Tiotropium Easyhaler Product B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium Bromide Monohydrate</intervention_name>
    <description>Tiotropium Easyhaler 10 mcg/dose Product C</description>
    <arm_group_label>Tiotropium Easyhaler Product C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium Bromide Monohydrate</intervention_name>
    <description>Spiriva 18 Mcg/capsule inhaled via HandiHaler</description>
    <arm_group_label>Spiriva HandiHaler</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female subjects

          -  18-60 years old

          -  Body mass index &gt;19 and &lt;30 kg/m2

          -  Weight at least 50 kg

          -  Written informed consent obtained

        Exclusion Criteria:

          -  Evidence of a clinically significant cardiovascular, renal, hepatic, haematological,
             gastrointestinal, pulmonary, metabolic, endocrine, neurological or psychiatric
             disease.

          -  Any condition requiring regular concomitant treatment.

          -  Any clinically significant abnormal laboratory value or physical finding that in the
             opinion of the investigator may interfere with the interpretation of study results or
             constitute a health risk for the subject.

          -  Known hypersensitivity to tiotropium bromide, atropine or its derivatives, or lactose.

          -  Pregnant or lactating females and females of childbearing potential not using proper
             contraception.

          -  Blood donation, loss of a significant amount of blood or administration of another
             investigational medicinal product within 90 days before the first study treatment
             administration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulla Sairanen, MSc</last_name>
    <role>Study Director</role>
    <affiliation>Orion Corporation, Orion Pharma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Minna Nissilä, MSc</last_name>
    <phone>+350104261</phone>
    <email>minna.nissila@orionpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Pharmacology Unit</name>
      <address>
        <city>Espoo</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2018</study_first_submitted>
  <study_first_submitted_qc>January 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 17, 2018</study_first_posted>
  <last_update_submitted>February 22, 2018</last_update_submitted>
  <last_update_submitted_qc>February 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Bromides</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

